New Female Viagra to Treat Women’s Sexual Desire Disorder

The U.S. Food and Drug Administration, on Tuesday August 18, approved the first “female viagra”, Addyi to treat low sexual desire in women. Addyi (flibanserin 100 mg) (pronounced add-ee), is a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. flibanserin-pill

“Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in men or women”, the FDA said in a press announcement it released yesterday.

“Today, we celebrate what this approval means for all women who have long awaited a medical treatment option for this life impacting condition,” said Cindy Whitehead, chief executive officer of Sprout Pharmaceuticals, manufacturers of Addyi.

The drug is said to have positive effect on chemicals involved in sexual excitement while it has negative effect in chemicals that cause inhibitions.

HSDD is defined as a persistent absence of sexual thoughts, fantasies, responsiveness and willingness to engage in sexual activity that causes personal or relationship distress and cannot be accounted for by another medical condition or substance. Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire.

Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. The condition is the most common form of female sexual dysfunction, affecting up to 1 in 10 women in the United States.

Precautions

Addyi is a prescription drug, and it’s not indicated to enhance sexual performance. According to the medication guide, interaction between Addyi and alcohol increases the risk of severe hypotension (low blood pressure) and syncope, temporary loss of consciousness caused by a fall in blood pressure.

addyi-couple-sex

Leave a Reply